ID

44776

Description

Study of STA-1 as an Add-on Treatment to Donepezil; ODM derived from: https://clinicaltrials.gov/show/NCT01255046

Lien

https://clinicaltrials.gov/show/NCT01255046

Mots-clés

Versions (3)
  1. 30/08/2015 30/08/2015 -
  2. 13/04/2021 13/04/2021 - Dr. rer. medic Philipp Neuhaus
  3. 18/11/2021 18/11/2021 -
Détendeur de droits

Sinphar Pharmaceutical Co., Ltd

Téléchargé le

18 novembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Alzheimer Disease NCT01255046

Anglais

Eligibility Alzheimer Disease NCT01255046

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

male or female patient aged ≥ 50 years;
Description

male or female; patient age

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
probable alzheimer's disease diagnosed by the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria;
Description

probable alzheimer's disease diagnosed by the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria;

Type de données

boolean

Alias
UMLS CUI [1]
C0002395
UMLS CUI [2]
C0038454
mmse score between 10-26, inclusive;
Description

mmse score between 10-26, inclusive;

Type de données

boolean

Alias
UMLS CUI [1]
C2225229
patient has been treated with donepezil 10 mg per day for at least 3 months prior to screening;
Description

patient has been treated with donepezil 10 mg per day for at least 3 months prior to screening;

Type de données

boolean

Alias
UMLS CUI [1]
C0527316
patient able to participate in all study evaluations and ingest oral medication as indicated;
Description

patient able to participate in all study evaluations and ingest oral medication as indicated;

Type de données

boolean

Alias
UMLS CUI [1]
C0175795
UMLS CUI [2]
C0677408
patient has a responsible caregiver who will accompany the patient to all clinic visits during the study;
Description

patient has a responsible caregiver who will accompany the patient to all clinic visits during the study;

Type de données

boolean

Alias
UMLS CUI [1]
C0150162
patient and the responsible caregiver have provided written informed consent before undergoing any study procedures.
Description

patient and the responsible caregiver have provided written informed consent before undergoing any study procedures.

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

brain image (computed tomography (ct) scan or magnetic resonance imaging (mri) done within past 12 months prior to the study) and laboratory tests to exclude secondary dementia or non-alzheimer's dementia;
Description

brain image (computed tomography (ct) scan or magnetic resonance imaging (mri) done within past 12 months prior to the study) and laboratory tests to exclude secondary dementia or non-alzheimer's dementia;

Type de données

boolean

Alias
UMLS CUI [1]
C0024485
UMLS CUI [2]
C0040405
UMLS CUI [3]
C0587081
patient with significant clinically central nervous system illness other than ad (e.g. parkinson's disease, human immunodeficiency virus (hiv) induced dementia, hachinski ischaemic score (his) >4) or dementia complicated by other organic disease or delirium;
Description

patient with significant clinically central nervous system illness other than ad (e.g. parkinson's disease, human immunodeficiency virus (hiv) induced dementia, hachinski ischaemic score (his) >4) or dementia complicated by other organic disease or delirium;

Type de données

boolean

Alias
UMLS CUI [1]
C0007682
patient with a severe or uncontrolled diagnostic and statistical manual of mental disorders (dsm-iv) axis i disorder other than alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder;
Description

patient with a severe or uncontrolled diagnostic and statistical manual of mental disorders (dsm-iv) axis i disorder other than alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder;

Type de données

boolean

Alias
UMLS CUI [1]
C0004936
patient suffering from cerebral disturbances following a stroke or a cerebral trauma (if the event occurred within the last 6 months);
Description

patient suffering from cerebral disturbances following a stroke or a cerebral trauma (if the event occurred within the last 6 months);

Type de données

boolean

Alias
UMLS CUI [1,1]
C0038454
UMLS CUI [1,2]
C0234387
UMLS CUI [2,1]
C0018674
UMLS CUI [2,2]
C0234387
patient with a history of hypersensitivity to study drugs;
Description

patient with a history of hypersensitivity to study drugs;

Type de données

boolean

Alias
UMLS CUI [1]
C0013182
patient who has a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., addison's disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;
Description

patient who has a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., addison's disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;

Type de données

boolean

Alias
UMLS CUI [1]
C3843040
participation in any research study within the last 30 days;
Description

participation in any research study within the last 30 days;

Type de données

boolean

Alias
UMLS CUI [1]
C0008976
patient with significant alcohol or drug abuse as judged by the investigator.
Description

patient with significant alcohol or drug abuse as judged by the investigator.

Type de données

boolean

Alias
UMLS CUI [1]
C0237123
Retour au début de la page

Similar models

Eligibility Alzheimer Disease NCT01255046

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
male or female; patient age
Item
male or female patient aged ≥ 50 years;
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
alzheimer's disease; neurological; probable; related; stroke
Item
probable alzheimer's disease diagnosed by the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria;
boolean
C0002395 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
score
Item
mmse score between 10-26, inclusive;
boolean
C2225229 (UMLS CUI [1])
screening; day; per
Item
patient has been treated with donepezil 10 mg per day for at least 3 months prior to screening;
boolean
C0527316 (UMLS CUI [1])
medication; study; oral; all
Item
patient able to participate in all study evaluations and ingest oral medication as indicated;
boolean
C0175795 (UMLS CUI [1])
C0677408 (UMLS CUI [2])
study; all
Item
patient has a responsible caregiver who will accompany the patient to all clinic visits during the study;
boolean
C0150162 (UMLS CUI [1])
written informed consent before randomization; procedure(s); procedures; study
Item
patient and the responsible caregiver have provided written informed consent before undergoing any study procedures.
boolean
C0021430 (UMLS CUI [1])
magnetic resonance imaging; computed tomography; laboratory tests; dementia; brain; study; done; mri; non
Item
brain image (computed tomography (ct) scan or magnetic resonance imaging (mri) done within past 12 months prior to the study) and laboratory tests to exclude secondary dementia or non-alzheimer's dementia;
boolean
C0024485 (UMLS CUI [1])
C0040405 (UMLS CUI [2])
C0587081 (UMLS CUI [3])
human immunodeficiency virus; central nervous system; dementia; delirium; other; disease; score; hiv
Item
patient with significant clinically central nervous system illness other than ad (e.g. parkinson's disease, human immunodeficiency virus (hiv) induced dementia, hachinski ischaemic score (his) >4) or dementia complicated by other organic disease or delirium;
boolean
C0007682 (UMLS CUI [1])
alzheimer's disease; mental disorders; psychosis; other; current; severe; dsm-iv; stress; axis; post
Item
patient with a severe or uncontrolled diagnostic and statistical manual of mental disorders (dsm-iv) axis i disorder other than alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder;
boolean
C0004936 (UMLS CUI [1])
stroke; trauma; event; last; from
Item
patient suffering from cerebral disturbances following a stroke or a cerebral trauma (if the event occurred within the last 6 months);
boolean
C0038454 (UMLS CUI [1,1])
C0234387 (UMLS CUI [1,2])
C0018674 (UMLS CUI [2,1])
C0234387 (UMLS CUI [2,2])
history of hypersensitivity to mistletoe; drugs; study
Item
patient with a history of hypersensitivity to study drugs;
boolean
C0013182 (UMLS CUI [1])
medical condition; adverse event; cardiovascular; investigator; not limited; evidence of; hematologic; neurologic; clinical; disease; hepatic; course; renal
Item
patient who has a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., addison's disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;
boolean
C3843040 (UMLS CUI [1])
study; last
Item
participation in any research study within the last 30 days;
boolean
C0008976 (UMLS CUI [1])
current alcohol or drug abuse; investigator
Item
patient with significant alcohol or drug abuse as judged by the investigator.
boolean
C0237123 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial